论文部分内容阅读
[目的]探讨多西他赛联合奥沙利铂治疗晚期食管癌的疗效及不良反应。[方法]经影像及病理组织学确诊的65例晚期食管癌患者,采用多西他赛联合奥沙利铂联合方案进行化疗,多西他赛75mg/m2静脉滴注90min,d1;奥沙利铂135mg/m2静脉滴注3h,d2,21d为1个周期,每2疗程评价疗效。[结果]65例患者完全缓解(CR)0例,部分缓解(PR)31例(47.69%),总有效率(CR+PR)47.69%,疾病进展时间:3.5～8.5个月,中位生存期4.8～25个月。在疼痛缓解、全身情况明显改善,生存质量和KPS评分提高等方面均取得了较好疗效。主要不良反应为骨髓抑制、外周神经毒性、消化道反应等。无治疗相关死亡者。[结论]多西他赛联合奥沙利铂治疗晚期食管癌安全、有效率高,毒性反应可以耐受。
[Objective] To investigate the efficacy and adverse reactions of docetaxel plus oxaliplatin in the treatment of advanced esophageal cancer. [Method] Sixty-five patients with advanced esophageal cancer diagnosed by imaging and histopathology were treated with docetaxel and oxaliplatin combined chemotherapy, and docetaxel 75 mg / m2 was given intravenously for 90 minutes d1. Platinum 135mg / m2 intravenous infusion 3h, d2, 21d for a cycle, evaluation of treatment every 2 cycles. [Results] There were 0 cases of complete remission (CR), 31 cases of partial remission (PR), 47.69% of total effective rate (CR + PR), 3.5 to 8.5 months of disease progression Period of 4.8 to 25 months. In pain relief, general condition improved significantly, quality of life and KPS score and achieved better results. The main adverse reactions were myelosuppression, peripheral neurotoxicity, gastrointestinal reactions and so on. No treatment-related deaths. [Conclusion] Docetaxel combined with oxaliplatin in the treatment of advanced esophageal cancer is safe and effective, and its toxicity can be tolerated.